Citius Pharmaceuticals, Inc. (OTC: CTXR) is a pharmaceutical company developing and commercializing therapeutic products for large and growing markets. Citius uses approved drugs with substantial safety and efficacy data in an effort to reduce the risks associated with pharmaceutical product development. Citius’ first FDA-approved product, Suprenza, is a novel formulation of a leading obesity drug. Citius’ is also advancing a product candidate for the treatment of hemorrhoids. Citius utilizes FDA’s 505(b)(2) pathway for our new drug approvals. For more information, visit the company’s website at www.citiuspharma.com/.